Efficacy of Ureklin combined with Alteplase for acute cerebral infarction and its influence on nerve function and inflammatory factors

doi:10.3969/j.issn.1004-583X.2021.06.005

Abstract

Abstract:

Objective To investigate the clinical effect of Urinary Kallidinogenase combined with Alteplase thrombolysis for acute cerebral infarction and its influence on nerve function, inflammatory factors and the quality of life. Methods In the study, 90 patients with acute cerebral infarction admitted to our hospital were retrospectively analyzed, all the patients were divided into two groups according to the difference of treatment plan, the control group (n=45) was treated with routine treatment puls Urinary Kallidinogenase, the observation group (n=45) were additionally treated Alteplase thrombolytic therapy on the basis of the control group. The clinical efficacy, nerve function recovery, inflammatory factors, as well as the quality of life were compared between the two groups. Results The total effective rate in the observation group was higher than that in the control group (93.33% vs 73.33%, P<0.05). NIHSS, CSS score in observation group was lower than those in control group, while BI score was higher than that in control group (P<0.05). The levels of CRP、PCT、IL-8 in the observation group was lower than those in control group after treatment (P<0.05). The WHOQOL-BREF score in observation group was higher than that in control group(P<0.05). Conclusion For acute cerebral infarction, the additional application of Ureicline kallidinogenase combined with Alteplase thrombolysis in the treatment on the basis of conventional treatment has ideal effect, which can promote the recovery of nerve function and motor function, relieve the inflammatory response, and improve the quality of life of patients.

Key words: urinary kallidinogenase, brain infarction, alteplase, thrombolytic therapy, nerve function

CLC Number:

R743.33

Liu Zhongqiu, Chu Jianfeng. Efficacy of Ureklin combined with Alteplase for acute cerebral infarction and its influence on nerve function and inflammatory factors[J]. Clinical Focus, 2021, 36(6): 509-512.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2021.06.005

https://huicui.hebmu.edu.cn/EN/Y2021/V36/I6/509

Figures/Tables 4

References 20

[1]	巩利英, 张桂茹. 阿替普酶联合尤瑞克林治疗急性脑梗死中的疗效评估[J]. 中华急诊医学杂志, 2019, 28(6):784-786.
[2]	刘雪云, 李坦, 王濯, 等. 脑小血管病总体负荷与急性缺血性卒中静脉溶栓后出血转化的关系[J]. 中华神经科杂志, 2019, 52(3):209-215.
[3]	张琦, 陶红, 陈佳, 等. 醒脑开窍针刺法联合阿替普酶静脉溶栓对急性脑梗死患者神经功能缺损程度的影响[J]. 中国中医急症, 2018, 27(11):1956-1959.
[4]	吴茂森, 陈庆贤, 刘丽霞. 自拟芪棱汤联合阿替普酶静脉溶栓对急性脑梗死患者血清炎性因子和神经功能康复的影响[J]. 现代中西医结合杂志, 2020, 29(13):1459-1462.
[5]	中华医学会神经病学分会, 中华医学会神经病学分会脑血管病学组. 中国急性缺血性脑卒中诊治指南2018[J]. 中华神经科杂志, 2018, 51(9):666-682.
[6]	葛建亮, 刘晓微, 曹红玉, 等. 高龄脑梗死急性期患者静脉溶栓的有效性及安全性分析[J]. 中华老年心脑血管病杂志, 2020, 22(11):1189-1192.
[7]	李康睿, 叶民. 丁苯酞联合阿替普酶溶栓治疗急性脑梗死的临床效果及血清炎症因子的变化[J]. 山西医药杂志, 2019, 48(19):2347-2349.
[8]	Wei L, Chen C, Dai YQ, et al. Serum 25-hydroxyvitamin D deficiency predicts poor outcomes among acute ischemic stroke patients receiving intravenous thrombolysis[J]. Chin Med J (Engl), 2019, 132(4):491-494.
[9]	廖硕希, 杨慧, 王培明, 等. 机械取栓治疗溶栓后超40 h急性前循环脑栓塞一例报道[J]. 中华神经医学杂志, 2020, 19(6):607-609.
[10]	张恒建, 王勇胜. 阿替普酶静脉溶栓治疗对急性脑梗死患者神经功能、凝血功能及炎症应激反应的影响[J]. 海南医学, 2018, 29(19):2752-2754.
[11]	李海军, 高晓嵘, 吴瑞, 等. 阿替普酶与巴曲酶治疗急性脑梗死的疗效比较及对患者血清NSE、IL-6、TNF-α、hs-CRP水平的影响[J]. 现代生物医学进展, 2018, 18(7):1330-1333.
[12]	王玮, 李悦, 徐霁华, 等. 急性缺血性脑卒中患者静脉溶栓后早期神经功能恶化的危险因素分析[J]. 中华老年心脑血管病杂志, 2019, 21(6):618-621.
[13]	郑晶, 杨斐斐, 占茂芳, 等. 急性缺血性脑卒中患者静脉溶栓后早期神经功能恶化的研究[J]. 国际神经病学神经外科学杂志, 2020, 47(3):272-276.
[14]	施学松. 阿替普酶溶栓治疗对急性脑梗死患者氧化应激相关因子水平和神经功能的影响[J]. 卒中与神经疾病, 2019, 26(1):39-42.
[15]	董亚茹, 薛秀云, 韩彩萍, 等. 阿替普酶对急性脑梗死疗效及其对神经功能损伤程度、实验室指标影响[J]. 疑难病杂志, 2018, 17(8):771-775.
[16]	王成友, 刘维洲. 阿替普酶静脉溶栓联合氯吡格雷治疗急性脑梗死的疗效[J]. 神经损伤与功能重建, 2019, 14(9):466-468.
[17]	李海涛, 张永强, 孟令弟. 尤瑞克林联合静脉溶栓剂对急性脑梗死患者治疗效果及血清学指标的影响[J]. 中华老年心脑血管病杂志, 2020, 22(2):169-172.
[18]	林芬, 张云峰. 阿替普酶静脉溶栓治疗急性脑梗死大鼠的疗效及对脑组织炎性因子表达的影响[J]. 中国临床药理学杂志, 2019, 35(8):750-752.
[19]	Liu X, Zhang J, Tian C, Wang J. The relationship of leukoaraiosis, haemorrhagic transformation and prognosis at 3 months after intravenous thrombolysis in elderly patients aged ≥60 years with acute cerebral infarction[J]. Neurol Sci, 2020, 41(11):3195-3200. doi: 10.1007/s10072-020-04398-2 URL
[20]	彭越, 刘慧勤, 王冰. 不同亚低温治疗时间结合静脉溶栓治疗对急性脑梗死患者认知功能及应激反应的影响[J]. 中华物理医学与康复杂志, 2019, 41(3):184-188.

组别	例数	显效	有效	无效	总有效率
观察组	45	20(44.44)	22(48.89)	3(6.67)	42(93.33)
对照组	45	15(33.33)	18(40.00)	12(26.67)	33(73.33)
χ²值					6.480
P值					0.011

组别	例数	显效	有效	无效	总有效率
观察组	45	20(44.44)	22(48.89)	3(6.67)	42(93.33)
对照组	45	15(33.33)	18(40.00)	12(26.67)	33(73.33)
χ²值					6.480
P值					0.011

组别	例数	NIHSS		BI		CSS
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
观察组	45	10.12±2.62	4.52±1.52^*	27.41±8.22	70.21±6.52^*	35.11±6.92	24.11±4.52^*
对照组	45	10.25±2.70	6.16±1.69^*	27.45±8.32	60.59±7.11^*	35.52±6.78	28.62±4.83^*
t值		0.232	4.840	0.023	6.690	0.284	4.574
P值		0.817	<0.01	0.982	<0.01	0.777	<0.01

组别	例数	NIHSS		BI		CSS
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
观察组	45	10.12±2.62	4.52±1.52^*	27.41±8.22	70.21±6.52^*	35.11±6.92	24.11±4.52^*
对照组	45	10.25±2.70	6.16±1.69^*	27.45±8.32	60.59±7.11^*	35.52±6.78	28.62±4.83^*
t值		0.232	4.840	0.023	6.690	0.284	4.574
P值		0.817	<0.01	0.982	<0.01	0.777	<0.01

组别	例数	CRP(mg/L)		PCT(ng/ml)		IL-8(ng/L)
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
观察组	45	28.54±4.52	7.62±1.52^*	2.56±0.52	0.67±0.12^*	45.51±9.52	24.67±6.42^*
对照组	45	27.95±4.55	11.02±1.69^*	2.66±0.56	0.80±0.15^*	45.66±9.41	33.45±7.22^*
t值		0.617	10.034	0.878	5.139	0.075	6.096
P值		0.539	<0.01	0.382	<0.01	0.940	<0.01